Advertisement
Organisation › Details
Bluebird Bio Inc. (Nasdaq: BLUE)
With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio’s gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™ BB305 product candidate, currently in three clinical studies for the treatment of transfusion-dependent ß-thalassemia, and severe sickle cell disease. bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene. bb2121 is currently being studied in a Phase 1 trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline. *
Start | 2014-06-16 existent | |
Group | Bluebird Bio (Group) | |
Industry | gene therapy | |
Industry 2 | Zynteglo™ (autologous CD34+ cells encoding ß A-T87Q-globin gene, formerly LentiGlobin™) | |
Person | Leschly, Nick (Bluebird Bio 201606 CEO) | |
Region | Cambridge, MA | |
Country | United States (USA) | |
Street | 150 2nd Street | |
City | 02141 Cambridge, MA | |
Tel | +1-339-499-9300 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2023-01-31) |
Currency | USD | |
Annual sales | 3,597,000 (revenues, total, consolidated (2022) 2022-12-31) | |
Profit | -266,578,000 (2022-12-31) | |
Cash | 113,006,000 (2022-12-31) | |
* Document for »About Section«: | ||
Record changed: 2023-12-16 |
Advertisement
More documents for Bluebird Bio (Group)
- [1] Apceth Biopharma GmbH. (5/11/20). "Press Release: Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with bluebird bio". Allendale, NJ & Munich....
- [2] Bluebird Bio, Inc.. (10/22/19). "Press Release: European Medicines Agency Approves Refined Commercial Manufacturing Specifications for Zynteglo". Cambridge, MA....
- [3] Medigene AG. (5/9/19). "Press Release: Bluebird Presents Preclinical Data of First TCR Candidate from Medigene Collaboration. Start Clinical Development 2020". Martinsried....
- [4] Bluebird Bio, Inc.. (10/5/18). "Press Release: Bluebird Bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent ß-Thalassemia". Cambridge, MA....
- [5] Apceth Biopharma GmbH. (10/5/18). "Press Release: Apceth to Manufacture First Potential One-time Gene Therapy for Transfusion Dependent ß-Thalassemia". Munich....
- [6] Medigene AG. (5/14/18). "Press Release: Medigene Significantly Expands TCR Alliance with Bluebird Bio in Cancer Immunotherapy". Planegg....
- [7] Lonza Group Ltd.. (4/10/18). "Press Release: Lonza Opens World’s Largest Dedicated Cell and Gene Therapy Manufacturing Facility in Pearland, Greater Houston, TX (USA)". Pearland, Greater Houston, TX....
- [8] Merck KGaA. (12/20/17). "Press Release: Merck Signs Commercial Supply Agreement with Bluebird Bio for Viral Vector Manufacturing". Darmstadt....
- [9] Bluebird Bio, Inc.. (11/29/17). "Press Release: Bluebird Bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients". Cambridge, MA....
- [10] Bluebird Bio, Inc.. (5/2/17). "Press Release: Bluebird Bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top